Physician profile
Warren C Dial
NPI 1851486419
$1,230.28
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $668 · 2022: $562.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $472.17 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $173.55 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $112.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $94.95 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $70.42 | 2021-2022 | |
| Novo Nordisk INC | $60.73 | 2021 | |
| Glaxosmithkline, LLC. | $56.00 | 2021-2022 | |
| Lilly USA, LLC | $52.61 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $35.55 | 2021 | |
| Sanofi Pasteur INC. | $24.49 | 2022 | |
| Amgen INC. | $17.32 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $16.19 | 2022 | |
| Supernus Pharmaceuticals, INC. | $15.87 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.01 | 2022 | |
| Alnylam Pharmaceuticals INC. | $12.75 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Dial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.